Economics Times Rising Indians 2019.

Setting new benchmarks for Peripheral Artery Diseases

Concept Medical Inc. (CMI) founded in 2008, specializes in “Converting Concepts into Reality” in the field of drug delivering medical devices. CMI, headquartered in Florida, has a manufacturing subsidiary in India, by the name, Envision Scientific Pvt. Ltd. (ESPL), where all their products are manufactured. Strong Research and Development is what sets this company apart from others. It has successfully developed innovative technologies in drug- delivery systems to address the unmet medical needs in coronary and peripheral artery disease.

Concept Medical has received >100 patents grant (in 11 patent family) in various countries. Patents include process, product and apparatus patents in field of nanocarrier based drug delivery. The Company has commercially available products outside of the United States in coronary artery disease (CAD) and peripheral vascular indications like Below-The-Knee (BTK), Arterio-Venous Fistula (AVF), Superficial Femoral Artery (SFA) artery diseases. CMI also has a significant pipeline of products under active development.

Behind the phenomenal success of the company is the talented Founder & Managing Director, Manish Doshi. He created the break-through innovation, Magic Touch - the Sirolimus-coated balloon with Nano-carrier coating technology. Under his effective leadership, Concept Medical has raised 60mn USD (for an undisclosed valuation) from cardiologist and serial entrepreneur Dr. Kiran Patel (Tampa, Florida) to support Investigational Device Exemption (IDE) process for the product Magic Touch. He has carved a niche for himself and for the organisation by developing more than 100 granted patents on novel cardiovascular medical devices and drug delivery system.

Manish Doshi has written two important chapters on DCB in the “Drug Coated Balloons Book” published by Springer. His published work provides an insight into the mechanisms of stent and using the latest and advanced technology of Drug Coated Balloons to treat coronary artery. Recognising his efforts in the field of drug delivery application for cardiovascular devices using nanotechnology, Manish has also been conferred honorary doctorate for the same. His Personal Mantra is "DISRUPTION". Moreover, he firmly believes and educates his team that "EVERY DELAY IS A COST."

From small R&D Groups, both Concept Medical (for Drug Coated Balloons) and Envision Scientific (for Drug Eluting Stents) have grown exponentially to become global giants in Medical Device Group. This leading Group has been able to showcase its capabilities by delivering the world with the best technologies and products in the field of cardiology and peripheral disease treatments.

By participating in various conferences and congresses all over the world, along with its distributors; world-wide presence has given this Group a competitive edge over others. Today Concept Medical has become a global market leader due to its eye-catching technologies and products.

Doshi is popularising his technology all over the world. The company is currently selling its patented products in all the European markets, besides other regulated markets like Middle East, Africa, North America, South America and Asia. Recently, company has been granted ‘Breakthrough Device Designation’ from the US Food and Drug Administration (FDA) for Magic Touch, its sirolimus drug-coated balloon (DCB) catheter, for the treatment of coronary In-Stent Restenosis. This is the first ever breakthrough device designation received by an Indian company in the medical device industry. Consequently, the Group (being termed as a leader in the cardiovascular market), is planning to expand its horizon by entering the US market soon. It is also planning the commercial launch of its products in Japan, which has the highest and most stringent regulatory norms in the near future.

With an unstoppable and optimistic attitude, Manish Doshi is also overseeing an ambitious expansion in the company's product portfolio by rolling out a slew of his novel, innovation-driven products by the end of 2020. The journey for constant innovation and evolution in the field of medical technology will continue so as to set new benchmarks in the health care sector.